Summarized by Masters of Longevity from PR Newswire.
A news release about a generative-AI–designed small-molecule GIPR antagonist candidate, previewing a preclinical development and safety-focused profile.
Key Takeaways
- Insilico nominated ISM1354 as a preclinical small-molecule GIPR antagonist for obesity and related disorders.
- ISM1354 showed oral bioavailability of 75–104% and at least 18-fold greater plasma exposure versus a clinical benchmark.
- In vitro data indicated weaker OATP1B1 inhibition and a wider hepatocyte safety margin up to 200 µM.
